elagolix sodium,estradiol,norethindrone acetate; elagolix sodium · Abbvie · NDA 213388
Oriahnn (Copackaged)
Earliest generic entry, as listed
27 Aug 2040
Blocked by patent: US 11690845. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11690845 | use U-3655 | 27 Aug 2040 |
| US 11542239 | substance, product | 23 Jul 2039 |
| US 12083227 | product, use U-2842 | 20 Aug 2038 |
| US 10881659 | use U-2842 | 14 Mar 2034 |
| US 11045470 | use U-2842 | 14 Mar 2034 |
| US 7419983 | substance, product | 6 Jul 2029 |
| US 11459305 | product, use U-2842 | 7 Nov 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213388 · 001 · RLD | capsule, oral | EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE | 27 Aug 2040 |